EcoDrugPlus

Arg8-Vasotocin Receptor-Like

Ensembl ID : ENSNBRG00000018354
Gene Symbol: LOC102782296
3 Cross references
170 Possible Orthologues:

B1 Bradykinin Receptor-Like

Ensembl ID : ENSNBRG00000023697
Gene Symbol: LOC102798848
3 Cross references
147 Possible Orthologues:

Bcl2 Apoptosis Regulator

Ensembl ID : ENSNBRG00000014320
Gene Symbol: BCL2
1 Cross references
176 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSNBRG00000020388
Gene Symbol: BCR
3 Cross references
205 Possible Orthologues:

Bdnf/nt-3 Growth Factors Receptor-Like

Ensembl ID : ENSNBRG00000005565
Gene Symbol: LOC102780703
3 Cross references
207 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSNBRG00000012043
Gene Symbol: BTK
3 Cross references
204 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSNBRG00000012822
Gene Symbol: CCR9
1 Cross references
193 Possible Orthologues:

C-X-C Motif Chemokine Receptor 2

Ensembl ID : ENSNBRG00000015674
Gene Symbol: CXCR2
1 Cross references
275 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSNBRG00000014409
Gene Symbol: LOC102777590
2 Cross references
347 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSNBRG00000003696
Gene Symbol: LOC102784918
2 Cross references
359 Possible Orthologues:

D(3) Dopamine Receptor-Like

Ensembl ID : ENSNBRG00000022837
Gene Symbol: LOC102785310
3 Cross references
203 Possible Orthologues:

D(4) Dopamine Receptor-Like

Ensembl ID : ENSNBRG00000012659
Gene Symbol: LOC102798085
3 Cross references
165 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).